Aerovate Therapeutics Inc (AVTE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has a cash flow conversion efficiency ratio of -0.032x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($75.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aerovate Therapeutics Inc (AVTE) defensive interval to measure how many days the company can operate on defensive assets alone.
Aerovate Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aerovate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aerovate Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tradetool Auto Co Ltd
TWO:3685
|
0.040x |
|
PolyPid
NASDAQ:PYPD
|
-2.876x |
|
Suny Cellular Communication Ltd
TA:SNCM
|
0.103x |
|
Song Shang Electronics Co Ltd
TWO:6156
|
-0.075x |
|
Konka Group Co Ltd
SHE:200016
|
0.069x |
|
Asetek A/S
F:A31
|
0.018x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
|
Afarak Group Oyj
HE:AFAGR
|
0.001x |
Annual Cash Flow Conversion Efficiency for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Aerovate Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | -126.98% |
| 2020-12-31 | $-13.34 Million | $-7.86 Million | 0.589x | -22.85% |
| 2019-12-31 | $-3.64 Million | $-2.78 Million | 0.763x | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.